Skip to main content
. 2023 Feb 21;62(3):42. doi: 10.3892/ijo.2023.5490

Figure 6.

Figure 6

PPVI inhibits STAT3/GPX4 in hepatocellular carcinoma cells. (A) The binding activity between PPVI and STAT3 was examined using network pharmacology-based analysis and molecular docking technology. (B) Simulation of the combination of PPVI and STAT3. (C-E) HCCLM3 and Huh7 cells were treated with PPVI or Stattic for 24 h. Western blot analysis of GPX4, STAT3 and p-STAT3 protein expression in HCCLM3 and Huh7 cells. (F and G) Detection of pY705-STAT3 expression in HCCLM3 and Huh7 cells treated with PPVI (2, 4 and 6 µM) using immunofluorescence staining. (H and I) Western blot analysis of GPX4, STAT3 and p-STAT3 levels in HCC cells with or without the overexpression of STAT3. (J) RT-qPCR analysis of STAT3 mRNA expression. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 vs. control or as indicated. NS, not significant (vs. control); Con, control; PPVI, polyphyllin VI; STAT3, signal transducer and activator of transcription 3; GPX4, glutathione peroxidase 4; Fer-1, ferrostatin-1; oeSTAT3, STAT3 overexpression plasmid.